A Two-Day Window on a Decision That Affects Millions of Prescriptions
The federal comment period on a rule that would close the last large-scale legal pathway for compounded weight loss injections ends this Thursday, and most of the people it would affect do not know the decision is being made.
On April 30, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from what is known as the 503B bulks list. That list determines which active ingredients large-scale outsourcing facilities may compound in bulk. The agency found no clinical need to keep the three drugs on it, because approved versions are commercially available and no longer in shortage. The Federal Register notice set an initial deadline of June 30, and the FDA extended it to July 30 after a request for more time.
FDA Commissioner Marty Makary said in the agency's announcement that "this action reflects our responsibility to protect patients" while preserving a transparent pathway for public input.
At the peak of the shortage in 2024, nearly one in three Americans on a GLP-1 drug reported getting it from a compounding pharmacy. That is the population with something concrete to do this week: find out what is actually in the vial, and ask the questions that determine whether the supply continues.
First, Determine Whether You Are Taking a Compounded Product at All
Many patients do not know. The clearest signal is the container. Approved products arrive as prefilled, single-dose pens with a manufacturer name on the label: Ozempic, Wegovy, or Rybelsus for semaglutide, Mounjaro or Zepbound for tirzepatide, and Saxenda or Victoza for liraglutide. Compounded products typically arrive as a multidose vial with syringes, requiring you to draw your own dose.
Added ingredients are another marker. Compounded formulations are frequently sold with vitamin B12, B6, niacinamide, glycine, or carnitine mixed in and marketed as personalized or custom blends. Sublingual drops and dissolving tablets are a third signal, because no such formulation has been approved.
Michael Blyumin, an ambulatory clinical care pharmacist at Stanford Medicine, was blunt about that last category in a Stanford Medicine explainer published this month. "Nobody legitimate makes sublingual semaglutide," he said.
If you cannot tell from the label, the prescribing platform and the dispensing pharmacy can both answer the question directly.
The Questions Worth Asking Before the Next Refill
Ask the prescribing group whether the prescription is written for an FDA-approved product or a compounded preparation, and if compounded, what documented patient-specific reason supports it. Under the current framework, a state-licensed 503A pharmacy may still compound for an individual patient, but only for a narrow, documented clinical reason such as an allergy to an ingredient or a strength that is not commercially available. Affordability, by the FDA's stated interpretation, does not qualify.
Ask the dispensing pharmacy three things: whether it is a registered 503B outsourcing facility or a 503A pharmacy, what exact concentration is in the vial, and what form of the active ingredient it uses. Concentration matters more than most patients realize, because five units drawn from one vial can contain twice the drug of five units from another. Salt forms such as semaglutide sodium are not equivalent to the approved ingredient.
Ask both about supply continuity. If a platform sources from a 503B outsourcing facility, a final rule matching the proposal would end that supply. If the answer is vague, that is itself informative.
Finally, ask what the transition plan is. Marina Basina, a clinical professor of endocrinology, gerontology, and metabolism at Stanford Medicine, cautioned that switching is not a simple one-to-one swap, because the true dose of a compounded product is often unclear. Her guidance for clinicians managing that transition was direct: "Start with a lower dose than patient's reported compounded drug dose."
What the Safety Record Actually Shows
The evidence here is regulatory and observational rather than the product of a controlled trial, and it should be read that way.
The FDA has documented reports of adverse events tied to compounded semaglutide and tirzepatide, some requiring hospitalization, with many traced to dosing errors when patients measured doses from multidose vials. As of early 2025, the agency had received more than 455 adverse event reports involving compounded semaglutide and more than 320 involving compounded tirzepatide. Those totals are almost certainly undercounts, because most state-licensed compounding pharmacies are not required to submit reports. Poison control centers have recorded a more than fifteen-fold increase in calls related to injected weight loss drugs since 2019.
The FDA has also identified fraudulently labeled products, including some listing compounding pharmacies that do not exist, and has warned about products arriving warm or improperly cooled, which can degrade a fragile peptide without any visible sign.
None of this establishes that every compounded product is unsafe or that any individual patient has been harmed. It establishes that the quality, potency, and content of these preparations are not verified by the agency, and that the failure modes documented so far cluster around dosing and handling rather than the drug molecule itself.
Who Faces the Greatest Disruption and What the Cost Picture Looks Like
The people with the most exposure are cash-paying patients on compounded products supplied by outsourcing facilities through telehealth platforms, particularly those without insurance coverage for obesity treatment and those in states where Medicaid does not cover GLP-1 drugs for obesity.
Patients taking an approved product are not affected by this proposal at all. Patients with a documented, individualized clinical reason for compounding may retain access through a 503A pharmacy, though at far smaller scale.
Cost alternatives exist and are frequently missed. Blyumin noted that patients often assume approved products are out of reach without checking. Manufacturers operate direct cash-pay channels and patient assistance programs, Medicare enrollees may have out-of-pocket caps that apply, and older generic weight loss medications such as phentermine-topiramate remain substantially cheaper. Anyone facing a denial can ask a prescriber about prior authorization, appeal, or a documented alternative.
What Readers Should Do Now
Do not stop a GLP-1 medication abruptly on your own, particularly if it is being used to manage type 2 diabetes. Any change should be made with a clinician who can plan the transition.
Confirm what you are taking, confirm where it comes from, and confirm the concentration. If a compounded product is genuinely the only option, both Stanford clinicians advised verifying it comes from a registered outsourcing facility rather than an unregistered online seller and staying under close medical supervision. The FDA's BeSafeRx programcan help locate a licensed online pharmacy.
Treat these as warning signs that a source is not legitimate: no prescription required, a pharmacy located outside the United States, packaging that is damaged, opened, unlabeled in English, or missing an expiration date, and ingredient lists described only as proprietary blends.
Severe abdominal pain radiating to the back, fainting, confusion, or no urination for eight hours are reasons for urgent evaluation, not for waiting.
What Happens Next
The comment docket closes July 30. The FDA will then review submissions before issuing a final determination, a process that could take several months. Members of the public can file comments through Regulations.gov under the docket for the May 1 notice, which has already drawn thousands of submissions.
If finalized as written, the rule would apply to 503B outsourcing facilities and would not change access for anyone using an approved GLP-1 product. Patient-specific compounding at 503A pharmacies would remain legal within narrow limits. Separate FDA enforcement against marketing claims and against imported active ingredients is continuing on its own track.
The confirmed fact is that the federal comment window on this proposal closes July 30. The people most affected are cash-paying patients receiving compounded GLP-1 products through telehealth platforms. The most reasonable action is a direct conversation with the prescriber and pharmacy about what the product is and what happens if that supply ends. The central uncertainty is when a final determination will be issued and what transition period, if any, it will allow.
Frequently Asked Questions
What is the FDA actually proposing? The agency proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, the set of active ingredients that large-scale outsourcing facilities may compound from in bulk. Without that listing, and with no shortage in effect, those facilities lose their remaining legal pathway.
Is compounded semaglutide banned right now? No. The proposal is not final. Outsourcing facilities and 503A pharmacies operate under existing rules until a final determination is issued.
Does this affect Ozempic, Wegovy, Zepbound, or Mounjaro? No. The proposal concerns compounded preparations. Access to FDA-approved products is unchanged.
How do I know if my prescription is compounded? Approved products come in prefilled, single-dose pens with a manufacturer brand name. Compounded products usually come as a multidose vial requiring you to draw your own dose, often with added vitamins. Your pharmacy can confirm directly.
Why do dosing errors happen more often with compounded products? Because patients measure their own doses from vials, and concentrations vary between products. The FDA has flagged cases in which patients administered 10 to 20 times the intended amount.
What if I cannot afford the approved version? Ask a clinician about manufacturer direct cash-pay programs, patient assistance programs, insurance appeals, and older generic weight loss medications. The FDA has stated that affordability alone does not establish a clinical need for compounding.
Can I submit a comment to the FDA? Yes. Comments on the May 1 notice are accepted through Regulations.gov until July 30, 2026.
